A small mixed-methods study of 23 cancer survivors found that most participants held positive attitudes toward cannabis and did not feel stigmatized by providers for using it. Unexpectedly, opioid-related stigma emerged as the more powerful force shaping pain management decisions, with some patients choosing cannabis partly to avoid the social judgment associated with opioid use. Several participants also withheld cannabis use from their clinicians, raising important safety concerns for integrated oncology care.

Cannabis use among cancer survivors is increasing rapidly alongside legalization, yet many oncology providers remain uncertain about how stigma influences their patients’ willingness to discuss it. At the same time, the opioid crisis has layered new forms of shame onto pain management that may be redirecting patients toward cannabis without clinical guidance. Understanding these overlapping stigma dynamics is essential for building the kind of trust that supports safe, transparent symptom management in survivorship care. This study offers a first, albeit small, window into how those forces interact in clinical decision-making.

As cannabis legalization expands across the United States, cancer survivors increasingly report using cannabis products for pain, nausea, insomnia, and anxiety. Yet the role of stigma in shaping whether and how patients integrate cannabis into their care remains poorly characterized. This convergent parallel mixed-methods study, nested within a larger observational trial (NCT06037681), recruited 23 cancer survivors from Western New York and Eastern Pennsylvania and stratified them by cannabis use status (10 users, 13 non-users). The investigators combined virtual focus groups analyzed through direct content analysis, guided by Andersen and colleagues’ stigma framework, with a validated 10-item attitudinal questionnaire, the Recreational and Medical Cannabis Attitudes Scale (RMCAS).

Quantitative attitudes toward cannabis were generally favorable across both user and non-user groups, and qualitative data largely confirmed this pattern: most participants did not report feeling judged by their healthcare providers for cannabis use. The most striking finding was emergent rather than pre-specified. Opioid-related stigma, both socially perceived and internalized, surfaced as a recurring theme that appeared to influence patients’ preferences for cannabis over opioids for pain control. Notably, several participants reported deliberately concealing their cannabis use from providers, suggesting that anticipatory stigma or privacy concerns persist even when overt judgment is not experienced. The authors appropriately acknowledge that these findings are hypothesis-generating and cannot be generalized beyond this small, self-selected, geographically restricted convenience sample. They call for larger, more diverse studies to explore whether opioid stigma is systematically redirecting cancer survivors toward unguided cannabis use.

This study asks a question I hear echoed in clinic nearly every week: are patients avoiding opioids not because they have better options, but because they are afraid of being labeled? That this small group of cancer survivors identified opioid stigma as a more powerful force than cannabis stigma is entirely consistent with what I observe in practice. The finding that patients are still concealing cannabis use from their oncologists is concerning but not surprising. It tells us that even in states with robust legal frameworks, the clinical conversation has not yet caught up with patient behavior. Twenty-three participants cannot carry the weight of policy conclusions, but they point us in a direction that matters.

In my own practice, I treat every intake as an opportunity to normalize the conversation about cannabis. I ask about it directly, without judgment, alongside questions about opioids, supplements, and over-the-counter medications. When patients feel safe disclosing, we can actually manage their care, identify drug interactions, adjust dosing, and avoid the kind of silent, parallel treatment plans that put people at risk. This study reinforces that proactive, stigma-aware communication is not a luxury in oncology supportive care; it is a clinical necessity.

This study sits at the very beginning of a research arc that will need to expand considerably before it can inform guidelines. Most existing literature on cannabis stigma in oncology has been survey-based, assessing provider attitudes rather than patient experiences. By centering patient voices through qualitative methods and using a validated stigma framework, this work adds a dimension that prior research has underserved. However, the sample size of 23, the geographic restriction to two sites in the Northeast, and the racial eligibility constraints (African American/Black or White only) impose sharp limits on transferability. The emergent nature of the opioid stigma finding, while clinically intuitive, means it was not tested with hypothesis-driven rigor.

For clinicians managing cancer survivors who use or are considering cannabis, the nondisclosure finding deserves particular attention. Patients who do not disclose cannabis use cannot be screened for interactions with chemotherapeutic agents, anticoagulants, immunosuppressants, or CYP450-metabolized medications. THC and CBD both interact with cytochrome P450 enzymes, and unmonitored use carries real pharmacological risk. The most actionable takeaway from this study is procedural: clinicians should routinely and nonjudgmentally ask about cannabis use in survivorship visits, treating it as a standard intake question rather than a sensitive disclosure event.

Have thoughts on this? Share it: